inDNA Life Sciences

What inDNA Life Sciences does

inDNA Life Sciences Private Limited is a Bhubaneswar-headquartered molecular diagnostics company founded in 2012 by Dr. Birendranath Banerjee. It operates as the first NABL-accredited (ISO 15189:2012) molecular genetic laboratory in Eastern India and runs a network of 12+ service centers across 6 Indian states, with regional bases in Delhi, Kolkata, and Guwahati. The company is DSIR-certified and has been incubated at KIIT-TBI since 2013, with funding support from DBT, BIRAC, TDB, and NSTDB.

The company offers a portfolio of 200+ indigenously validated DNA/RNA-based diagnostic tests organized into five clinical verticals — Oncodiagnostics (FISH, IHC, PCR, and NGS panels including a 21-day NGS comprehensive cancer panel and an HRR panel), Pediagenetics (karyotyping, FISH, chromosomal microarray, and mutation analysis for inherited disorders), Molecular Fertility (NIPT, PGS, beta-thalassemia and IVF-related testing), Wellness (genetic risk assessment using an algorithm built on an Indian ethnic-population database), and Infection Biology (RT-PCR for MTB, HPV, HIV, HCV, HBV). Its technology stack spans Cytogenetics, FISH, PCR, RT-PCR, Sanger Sequencing, and NGS, with proprietary techniques patented by the founder. In October 2025 the company added Elephas Biosciences' Elephas Live immunotherapy-response prediction platform at its Bhubaneswar facility.

The business model is a per-sample, per-test fee-for-service diagnostic lab, with pricing not publicly disclosed. Revenue is generated through direct testing of patient samples referred by surgical oncologists, gynecologists, pediatricians, and IVF specialists; institutional MOUs with Eastern India hospitals; and clinician training programs (7-day to 6-month durations) that double as a referral funnel. No public funding rounds or revenue figures are disclosed, and the company remains founder-led with no evidence of institutional private equity.

Name

inDNA Life Sciences

Legal name

inDNA Life Sciences Private Limited

Website

https://indnalife.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

inDNA Life Sciences is a NABL-accredited molecular diagnostics company based in Bhubaneswar that delivers 200+ DNA-based tests across oncology, fertility, pediatrics, wellness, and infectious disease to clinicians and patients across 6 Indian states.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Molecular diagnostic services
• DNA based testing
• Cancer genetic testing
• Prenatal genetic screening
• Clinical genetics laboratory

Headquarters

HQ city

Bhubaneswar

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: inDNA generates revenue through providing DNA-based molecular diagnostic tests to patients and referring clinicians. Tests span oncodiagnostics, pediatrics, molecular fertility, wellness, and infection biology. Each test is individually priced and performed on a per-sample basis with specific turnaround times ranging from 1 day to 4 weeks depending on complexity.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

inDNA Life Sciences is a DNA-based molecular diagnostics company that develops and delivers customized gene tests and companion gene panels through its NABL-accredited central reference laboratory and 12+ service centers across 6 Indian states. Its portfolio spans oncodiagnostics, pediatric genetics, molecular fertility, wellness, infection biology, and routine diagnostics, executed on validated Cytogenetics, FISH, PCR, RT-PCR, Sanger Sequencing, NGS, and Chromosomal Microarray platforms using indigenously developed assays tailored to the Indian population.

Product overview

inDNA Life Sciences is a DNA-based molecular diagnostics company offering a comprehensive portfolio of diagnostic services organized into specialized divisions: Oncodiagnostics (cancer diagnostics via FISH, IHC, PCR, and NGS), Pediagenetics (pediatric genetic testing), Molecular Fertility (prenatal and reproductive genetics), Wellness (genome health analysis), and routine diagnostics (haematology, biochemistry, hormone, and infection testing). The company operates as a NABL-accredited laboratory with in-house R&D capabilities and provides educational training programs. The Elephas Live platform was also deployed at their Bhubaneswar facility for predictive immunotherapy response testing.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncodiagnostics Comprehensive cancer diagnostic service offering FISH panels for solid tumors and hematological malignancies, immunohistochemistry (IHC) panels, and PCR and sequencing-based panels for mutation analysis including EGFR, KRAS, NRAS, BRCA, and other cancer-related genes. Targeted at oncologists and cancer patients needing tumor profiling and treatment matching.
• Pediagenetics Pediatric genetic diagnostic service including FISH panels for chromosomal abnormalities, karyotyping services, chromosomal microarray as first-tier test for pediatric indications, and mutation analysis for conditions such as Duchenne muscular dystrophy, spinal muscular atrophy, cystic fibrosis, and other genetic disorders. Targeted at pediatricians and families of children with suspected congenital or inherited conditions.
• Molecular Fertility Fertility and reproductive genetics diagnostic service including prenatal diagnosis for beta thalassemia and sickle cell anemia, Non-Invasive Prenatal Testing (NIPT), pre-implantation genetic screening (NGS-based for 1-4 embryos), endometrial receptivity testing, and male infertility testing. Targeted at gynecologists, IVF clinics, and couples seeking reproductive genetic testing.
• Wellness Health and wellness genetic analysis using an indigenously developed complex algorithm based on the Indian genetic database, including HLA-B27 screening and genome health analysis for lifestyle disease risk assessment (diabetes, cardiovascular, obesity). Targeted at health-conscious individuals seeking preventive genetic risk profiling.
• Infection Biology Molecular infectious disease diagnostic service using RT-PCR for detection of MTB (Mycobacterium tuberculosis), HPV, HIV, HCV, and HBV with turnaround times of 2-3 days. Targeted at patients and clinicians requiring accurate pathogen detection and viral load monitoring.
• Haematology Complete Blood Count (CBC) analysis using flow-based methods for hematological assessment. Targeted at patients and clinicians requiring routine hematological screening.
• Biochemistry Biochemical marker testing using CLIA and other methods for cancer markers (CA 15-3, CA-125, CA-19-9, AFP, CEA), vitamins (D, B12), and inflammatory markers (CRP). Targeted at patients and clinicians requiring routine biochemical and tumor marker profiling.
• Hormone Testing Thyroid panel testing (T3, T4 and TSH) using CLIA methodology for assessment of thyroid function. Targeted at patients and clinicians needing thyroid function evaluation.
• Panels Routine diagnostic panels including Liver Function Test (LFT), Kidney Function Test (KFT), glucose testing, lipid profile, and infectious disease screening (typhoid, dengue, malaria). Targeted at walk-in patients and general clinician referrals for routine biochemistry screening.
• Training Programs Hands-on training programs for graduate and undergraduate students in life sciences covering FISH-based cancer diagnostics, cytogenetics, karyotyping, molecular pathology, cancer genetics, hematological malignancies, infertility, and prenatal diagnosis. Programs range from 7 days to six months. Targeted at medical students, life sciences graduates, and medical professionals seeking specialized molecular diagnostics training.

Quantifiable outcome

• First and only NABL accredited molecular genetic laboratory in Eastern India
• +2 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Elephas BiosciencescoreTechnology or Integration · 10 October 2025Elephas Biosciences deployed its Elephas Live platform at inDNA Life Sciences in Bhubaneswar, India, to predict immunotherapy responses in cancer patients. The first patient was screened as part of a study to improve treatment matching and response rates in India. This partnership enables inDNA to offer advanced immunotherapy response prediction services using Elephas's platform technology.
• Leading Healthcare Institutions of Eastern IndiacoreStrategic or Co-development PartnerinDNA has signed MOUs with leading healthcare institutions and hospitals of Eastern India to promote next generation Biotechnology-based Diagnostics and Disease Management, known as Personalized Medicine.
• AIIMS (All India Institute of Medical Sciences)minorStrategic or Co-development PartnerinDNA is associated with AIIMS for offering accredited courses and super specialized training programs in molecular diagnostics and personalized medicine.
• ICMR RMRC (Indian Council of Medical Research - Regional Medical Research Centre)minorStrategic or Co-development PartnerinDNA is associated with ICMR RMRC for offering accredited courses and specialized training programs.
• ILS (Institute of Life Sciences)minorStrategic or Co-development PartnerinDNA is associated with ILS Bhubaneswar for offering accredited courses and super specialized training programs in molecular diagnostics.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Core Diagnostics: India-focused specialty diagnostics lab offering advanced oncology, molecular and genetic tests with hospital partnerships — directly comparable in test menu, clinician target segment and specialty lab positioning.
• MedGenome: India and South Asia focused genetic diagnostics and genomics research company offering NGS-based panels across oncology, inherited disorders and reproductive health — directly overlapping inDNA's oncodiagnostics, pediagenetics and molecular fertility services.
• Strand Life Sciences: Bengaluru-based genomics and bioinformatics company providing clinical genomic testing, hereditary cancer panels and NIPT in India — closely comparable to inDNA's molecular diagnostics, NGS-based panels and wellness testing.
• Neuberg Diagnostics: Pan-India diagnostics chain with strong molecular diagnostics, cytogenetics and cancer genetics capabilities across multiple states — directly competitive with inDNA's oncology, pediatrics and infectious disease molecular testing.
• Mapmygenome: India-based personal genomics and preventive health testing company offering DNA-based health and wellness reports, predictive genetic tests and pharmacogenomics — overlapping with inDNA's wellness and lifestyle disease risk assessment service.

Broad incumbents

• Metropolis Healthcare: Large Indian diagnostic chain with pan-India presence and expanding molecular and genomic testing services — comparable in service breadth and target clinician base, though a much larger incumbent.
• SRL Diagnostics: Agilus Diagnostics / SRL is one of India's largest established diagnostic networks with extensive molecular and specialty testing — competes for hospital and clinician referrals nationwide, including in Eastern India.
• Dr. Lal PathLabs: One of India's largest diagnostic chains with a national footprint and a growing molecular diagnostics menu including oncology and infectious disease PCR — competes broadly with inDNA via referral networks and corporate hospital contracts.
• Thyrocare Technologies: High-volume, low-cost Indian diagnostic chain (now part of PharmEasy) offering preventive and routine tests nationally — relevant peer on pricing dynamics and pan-India franchise in diagnostics, even if molecular genetics is less central.

Emerging players

• 4baseCare: Bengaluru-based precision oncology startup offering NGS-based tumor profiling and liquid biopsy in India — directly comparable to inDNA's oncodiagnostics NGS panels (PANEL-ONCO A, HRR Panel) and a likely competitor for specialist oncology referrals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/indna_life
• Facebookfacebook.com/indnalife
• LinkedInlinkedin.com/company/indnalife

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about inDNA Life Sciences